# Cytotoxic KLRG1+ IL-7R- effector CD8+ T cells distinguish kidney transplant recipients controlling cytomegalovirus reactivation

**Authors:** Yumeng Sun, Subha Sen, Rajesh Parmar, Janice Arakawa-Hoyt, Monica Cappelletti, Maura Rossetti, David W. Gjertson, Tara K. Sigdel, Minnie M. Sarwal, Joanna M. Schaenman, Suphamai Bunnapradist, Lewis L. Lanier, Harry Pickering, Elaine F. Reed

PMC · DOI: 10.3389/fimmu.2025.1542531 · Frontiers in Immunology · 2025-02-14

## TL;DR

This study identifies specific CD8+ T cells that help kidney transplant patients control cytomegalovirus reactivation, offering insights for better monitoring and treatment strategies.

## Contribution

The study identifies a unique CD8+ T cell subset associated with CMV control in kidney transplant recipients, providing new insights into immune monitoring.

## Key findings

- CMV serostatus significantly influences CD8+ memory T cell transcriptional variance.
- CD28lo KLRG1hi IL-7Rlo HLA-DRhi CD8+ T cells correlate with CMV reactivation and immune response markers.

## Abstract

Cytomegalovirus (CMV) viremia remains a major contributor to clinical complications in solid organ transplant (SOT) patients, including organ injury, morbidity and mortality. Given their critical role in antiviral defense, CD8+ T cells are essential for protective immunity against CMV.

Using single-cell RNA sequencing, we investigated the transcriptional signatures and developmental lineages of CD8+ T cells in eight immunosuppressed kidney transplant recipients (KTRs) who received organs from CMV-seropositive donors. Results were validated in a cohort of 62 KTRs using immunophenotyping.

Our data revealed a significant influence of CMV serostatus on transcriptional variance of CD8+ memory T cells, associating with the first principal component from a global analysis of CD8+ T cells (p =0.0406), forming a continuum with five principal differentiation trajectories driven by CMV primary infection or reactivation. Following CMV primary infection, CD8+ T cells were hallmarked by restrained effector-memory differentiation. CD8+ T cells during CMV reactivation diverged non-linearly into senescent-like cells with signatures of arrested cell cycle, diminished translational activity and downregulated ZNF683 and longitudinally expanding effector cells with robust cytotoxic potential and upregulated ZNF683, acting as a reservoir for long-lived effector cells supporting long-term protection. Notably, CD28lo KLRG1hi IL-7R (CD127)lo HLA-DRhi CD8+ T cells present prior to the detection of viremia in CMV-seropositive patients emerged as a key feature distinguishing patients who did or did not undergo CMV reactivation after prophylaxis discontinuation (p =0.0163). Frequencies of these cells were also positively correlated with CMV-stimulated secretion of IFN-γ (p =0.0494), TNF-α (p =0.0358), MIP-1α (p =0.0262), MIP-1β (p =0.0043).

These results provide insights into the transcriptional regulation that influences the generation of CD8+ T cell immunity to CMV and may inform strategics for monitoring host immune response to CMV to better identify and introduce therapeutic intervention to patients at risk of developing clinically significant CMV viremia.

## Linked entities

- **Genes:** ZNF683 (zinc finger protein 683) [NCBI Gene 257101], CD28 (CD28 molecule) [NCBI Gene 940], KLRG1 (killer cell lectin like receptor G1) [NCBI Gene 10219], IL7R (interleukin 7 receptor) [NCBI Gene 3575], IL7R (interleukin 7 receptor) [NCBI Gene 3575], IFNG (interferon gamma) [NCBI Gene 3458], TNF (tumor necrosis factor) [NCBI Gene 7124], CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348], CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351]

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, ZNF683 (zinc finger protein 683) [NCBI Gene 257101] {aka Hobit}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, KLRG1 (killer cell lectin like receptor G1) [NCBI Gene 10219] {aka 2F1, CLEC15A, MAFA, MAFA-2F1, MAFA-L, MAFA-LIKE}
- **Diseases:** CMV-seropositive (MESH:D003586), CMV viremia (MESH:D014766), infection (MESH:D007239), cytomegalovirus reactivation (MESH:D000085343), organ injury (MESH:D009102)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11868092/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11868092/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC11868092/full.md

---
Source: https://tomesphere.com/paper/PMC11868092